The 99th Annual Meeting of the Japanese Pharmacological Society

Chair:Yasunari Kanda(National Institute of Health Sciences (NIHS))

Advances in new approach technologies, including human iPS cells and microphysiological systems, are transforming the landscape of drug development. This session highlights the close integration of pharmacology and regenerative medicine, with a focus on the development of human cell–based evaluation platforms grounded in robust quality control and mechanistic understanding. We will discuss how these platforms can be translated into practical application and implementation. In particular,by addressing emerging modalities such as cell therapy products, this session explores their applications during drug development. Through these discussions, we aim to outline evidence-based frameworks for pharmaceutical evaluation and to consider future strategies that bridge innovative science and regulatory decision-making.